H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Actinium Pharmaceuticals (ATNM – Research Report) today and set a price target of $4.00.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Joseph Pantginis has given his Buy rating due to a combination of factors that highlight Actinium Pharmaceuticals’ potential for growth and innovation. The company has a robust pipeline with several promising trials and data readouts anticipated in the second half of 2025. This includes the initiation of a Phase 2/3 study for Actimab-A in combination with CLAG-M for relapsed/refractory acute myeloid leukemia (AML), as well as trials exploring Actimab-A with Keytruda or Opdivo in patients with PD-L1 expression in head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC).
Additionally, Actinium’s financial position is stable, with approximately $65.34 million in cash expected to fund operations for at least the next 12 months. The company has also implemented a workforce optimization to reduce expenses, which is not anticipated to impact its operational capabilities. Furthermore, recent preclinical data for ATNM-400 in prostate cancer and ongoing trials for Iomab-ACT in CAR-T therapy and sickle cell disease underscore the company’s innovative approach and potential for future success.
In another report released on April 30, JonesTrading also reiterated a Buy rating on the stock with a $9.00 price target.